NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
RANEXA (ranolazine) by Menarini is cytochrome p450 3a inhibitors [moa]. First approved in 2006.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RANEXA (ranolazine) is an oral extended-release tablet approved in 2006 for chronic angina management. It works as a cytochrome P450 3A inhibitor, offering a novel mechanism distinct from traditional antianginal agents. The drug is used as an adjunctive therapy in patients with symptomatic angina inadequately controlled by conventional treatments.
$2.0MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D utilization (2,469 claims in 2023), indicating a niche market position with limited team growth prospects.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Comparative Efficacy of Intralesional Tranexamic Acid Versus Mandelic Acid Peel in the Treatment of Melasma
Started May 2026
120 enrolled
Melasma
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
Started Nov 2025
1,546 enrolled
Liver TransplantationTranexamic AcidEnd-stage Liver Disease (ESLD)
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
Started Jun 2024
850 enrolled
Surgical Blood LossTransfusion-dependent AnemiaAbdomen Disease
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
Started Jan 2024
65 enrolled
BleedingContraceptive Device; Complications
Tranexamic Acid to Reduce Blood Loss in Women Having Planned Cesarean Section
Started Nov 2023
68 enrolled
Cesarean SectionBlood Loss During Surgery
Worked on RANEXA at Menarini? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.